June 4, 2026
Supporting Innovation in Friedrich Ataxia Clinical Research
Recently announced clinical results show positive data as part of the ongoing PHASE1/2 RESTORE-FA trial
Register Your Interest
English
Recently announced clinical results show positive data as part of the ongoing PHASE1/2 RESTORE-FA trial
Doherty Clinical Trials Limited is proud to announce the commencement of the CHIVAS-M1 study (Controlled Human Infection for Vaccination Against Streptococcus pyogenes M1UK), which will help drive medical research and development of a vaccine against Streptococcus pyogenes, otherwise known as Strep A.
Senior Lab Manager, Vanessa Mollard represented Doherty Clinical Trials at the forum in Canberra
Dr Andrew Brockway's panel, 'Clinical Trials in Australia: Performance, Competitive Advantages, Challenges and Evolving Policy' at AusBiotech 2024
Highlighting the vital work of Doherty Clinical Trials and sharing why participants find it so rewarding.
Doherty Clinical Trials launches the #mRNA Platform Incubator Network in collaboration with Moderna and other leading minds in bio-medical research
Delving further into the Doherty Clinical Trials experience and the purposes of human challenge trials, the article is another feature highlighting the company’s launch.
Speaking about the importance of human challenge trials, the article coincides with the launch of Doherty Clinical Trials' facility in East Melbourne.
A skills-based board combines comprehensive experience in academic research, financial strategy, commercial development and biotechnology & pharmaceutical industries. Along with the specialised leadership team, this expertise drives Doherty Clinical Trials Ltd unique capabilities.
Chief Executive Officer
Chief Scientific Officer
Medical Director
Clinical Strategy Director
Director
Project Management Director
Director
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}